jolkinolide b has been researched along with Bladder Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, RZ; Gan, L; Huang, JL; Li, W; Lin, ZJ; Sang, J; Tang, GH; Yin, S; Zou, MF | 1 |
| Diao, HJ; Fan, RZ; Gan, L; Huang, JL; Li, W; Sang, J; Tang, GH; Yin, S; Zou, MF | 1 |
2 other study(ies) available for jolkinolide b and Bladder Cancer
| Article | Year |
|---|---|
Jolkinolide B sensitizes bladder cancer to mTOR inhibitors via dual inhibition of Akt signaling and autophagy.
Topics: Animals; Autophagy; Cell Line, Tumor; Diterpenes; Drugs, Chinese Herbal; Humans; Male; Mice; MTOR Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Transfection; Urinary Bladder Neoplasms | 2022 |
Jolkinolide B targets thioredoxin and glutathione systems to induce ROS-mediated paraptosis and apoptosis in bladder cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Diterpenes; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Glutathione; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Reactive Oxygen Species; Thioredoxin Reductase 1; Thioredoxins; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2021 |